Ubiquitination‐resistant p53 protein transduction therapy facilitates anti‐cancer effect on the growth of human malignant glioma cells

• Hiroyuki Michiue

• Kazuhito Tomizawa

• Masayuki Matsushita

• Takashi Tamiya

• Yun-Fei Lu

• Tomotsugu Ichikawa

• Isao Date

• Hideki Matsui

抄録

Protein transduction therapy using poly‐arginine can deliver the bioactive p53 protein into cancer cells and inhibits the proliferation of the cells. However, one disadvantage of such therapy is the short intracellular half‐life of the delivered protein. Here, we generated mutant proteins in which multiple lysine residues in the C‐terminal were substituted by arginines. The mutant proteins were effectively delivered in glioma cells and were resistant to Mdm2‐mediated ubiquitination. Moreover, the mutant proteins displayed higher transcription regulatory activity and powerful inhibition of the proliferation of glioma cells. These results suggest that ubiquitination‐resistant p53 protein therapy may become a new effective cancer therapy.

収録刊行物

• FEBS Letters

  FEBS Letters 579 (18), 3965-3969, 2005-06-27

  Wiley

キーワード

• Cell Biology
• Genetics
• Molecular Biology
• Biochemistry
• Structural Biology
• Biophysics

詳細情報

• CRID: 1361418521131366912
• NII論文ID: 30002590844
• DOI: 10.1016/j.febslet.2005.06.021
• ISSN: 18733468
• ISSN: 00145793
• Web Site: https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1016%2Fj.febslet.2005.06.021
• Web Site: https://febs.onlinelibrary.wiley.com/doi/pdf/10.1016/j.febslet.2005.06.021
• データソース種別:
  • Crossref
  • CiNii Articles
  • KAKEN